Deucravacitinib for the Treatment of Palmoplantar Pustulosis

Phase 4 Terminated 3 enrolled Brigham and Women's Hospital University of Pennsylvania · collab

NaSingle-groupOpen-labelTreatment

Summary

A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.

Timeline

Start: 2023-07-01
Primary completion: 2024-12-01
Completion: 2025-01-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CRAVACITINIB	Small molecule	6 mg	—

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

Summary

Timeline

Drugs

Indications